Novavax has on Monday announced that its COVID-19 vaccine is more than 90% effective against COVID-19.
A statement issued by Novavax showed that, NVX-CoV2373, (Novavax’s recombinant nanoparticle protein-based COVID-19 vaccine), demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall.
The results were met through a study which enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity.
Stanley C. Erck, President and Chief Executive Officer, Novavax said, “today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines.”
“These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection.” The President added.
The company intends to file for regulatory authorizations in the third quarter, upon completion of the final phases of process qualification and assay validation needed to meet chemistry, manufacturing and controls (CMC) requirements.
Upon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021.